Alpharetta, Georgia-based Avanos Medical (NYSE:AVNS), a medical technology company focused on pain management and chronic care solutions, reported fourth-quarter and full-year 2025 financial results on February 24, 2026.
For the full year ended December 31, 2025, net sales totaled $701.2 million, with adjusted diluted earnings per share of $0.94.
The company achieved organic sales growth in its core pain management and digestive health franchises, driven by demand for products such as COOLIEF cooled radiofrequency technology, Game Ready recovery systems, and enteral feeding devices.
Adjusted EBITDA for the year was $86.8 million.
The company also recorded a non-cash goodwill impairment charge of $77 million in 2025, primarily related to the reassessment of carrying values in certain reporting units amid evolving market conditions and competitive pressures.
In the fourth quarter, net sales reached $180.9 million, consistent with seasonal trends and ongoing execution in strategic product lines.
Avanos ended the year with cash and cash equivalents of $89.8 million and net debt of $10.7 million.
Meanwhile, management highlighted progress on cost-saving programs and expects to deliver $15 million to $20 million of incremental annualized savings by the end of 2026.